Inflammatory cytokines and the GH/IGF-I axis: Novel actions on bone growth

Cell Biochemistry and Function

Volumn 27, Issue 3, 2009, Pages 119-127

  Pass, Chloe ^a,b   MacRae, V E ^a   Ahmed, S F ^b   Farquharson, C ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Chondrocytes; GH; Growth plate; IGF 1; Inflammatory cytokines; SOCS2

Indexed keywords

GROWTH HORMONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 2; TUMOR NECROSIS FACTOR ALPHA;

BONE GROWTH; CARTILAGE CELL; CELL PROLIFERATION; CYTOKINE PRODUCTION; GROWTH INHIBITION; GROWTH PLATE; GROWTH REGULATION; GROWTH RETARDATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE DEVELOPMENT; CYTOKINES; GROWTH HORMONE; HUMANS; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 65549121723     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1551     Document Type: Review

References (135)

1. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423: 332-336.
2. Walenkamp MJE, Wit JM. Genetic disorders in the GH IGF-I axis in mouse and man. Eur J Endocrinol 2007; 157: S15-S26.
3. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child 2002; 87: 93-96.
4. Vagianos K, Bector S, McConnell J, et al. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007; 31: 311-319.
5. Ahmed SF, Tucker P, Mushtaq T, et al. Short-term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone. Clinical Endocrinol 2002; 57: 185-191.
6. Macrae VE, Wong SC, Farquharson C, et al. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (Review). Int J Mol Med 2006; 18: 1011-1018.
7. Macrae VE, Ahmed SF, Mushtaq T, et al. IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1[beta]. Growth Horm IGF Res 2007; 17: 435-439.
8. Rico-Bautista E, Flores-Morales A, Fernández-Pérez L. Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev 2006; 17: 431-439.
9. Metcalf D, Greenhalgh CJ, Viney E, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000; 405: 1069-1073.
10. Mackie EJ, Ahmed YA, Tatarczuch L, et al. Endochondral ossification: How cartilage is converted into bone in the developing skeleton. Int J Biochem Cell Biol 2008; 40: 46-62.
11. Kember NF, Sissons HA. Quantitative histology of the human growth plate. J Bone Joint Surg Br 1976; 58-B: 426-435.
12. Farnum CE, Wilsman NJ. Morphologic stages of the terminal hypertrophic chondrocyte of growth plate cartilage. Anat Rec 1987; 219: 221-232.
13. Farnum CE, Wilsman NJ. Determination of proliferative characteristics of growth plate chondrocytes by labeling with bromodeoxyuridine. Calcif Tissue Int 1993; 52: 110-119.
14. Ballock RT, O'Keefe RJ. The biology of the growth plate. J Bone Joint Surg Am 2005; 85: 715-726.
15. Hunziker EB, Schenk RK, Cruz-Orive LM. Quantitation of chondrocyte performance in growth-plate cartilage during longitudinal bone growth. J Bone Joint Surg Am 1987; 69: 162-173.
16. Hunziker EB, Shenk RK. Physiological mechanisms adopted by chondrocytes in regulating longitudinal bone growth in rats. J Physiol 1989; 414: 55-71.
17. Farquharson C. Bone growth. In Biology of Growth of Domestic Animals, Scanes CG (ed). Iowa State Press: Iowa, 2003; 170-185.
18. Roach HI, Erenpreisa J, Aigner T. Osteogenic differentiation of hypertrophic chondrocytes involves asymmetric cell divisions and apoptosis. J Cell Biol 1995; 131: 483-494.
19. Cancedda R, Cancedda FD, Castagnola P. Chondrocyte differentiation. Int Rev Cytol 1995; 159: 265-358.
20. Shapiro IM, Adams CS, Freeman T, et al. Fate of the hypertrophic chondrocyte: microenvironmental perspectives on apoptosis and survival in the epiphyseal growth plate. Birth Defects Res C Embryo Today 2005; 75: 330-339.
21. Breur GJ, VanEnkevort A, Farnum CE, et al. Linear relationship between the volume of hypertrophic chondrocytes and the rate of longitudinal bone growth in growth plates. J Orthop Res 1991; 9: 348-359.
22. Nilsson O, Marino R, De Luca F, et al. Endocrine regulation of the growth plate. Horm Res 2005; 64: 157-165.
23. Kember NF. Comparative patterns of cell division in epiphyseal cartilage plates in the rabbit. J Anat 1985; 142: 185-190.
24. Pizette S, Niswander L. BMPs are required at two steps of limb chondrogenesis: formation of prechondrogenic condensations and their differentiation into chondrocytes. Dev Biol 2000; 219: 237-249.
25. Akiyama H, Chaboissier MC, Martin JF, et al. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 2002; 16: 2813-2828.
26. Lupu F, Terwilliger JD, Lee K, et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.
27. Cuttler L, Jackson JA, Saeed uz-Zafar M, et al. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989; 68: 1148-1154.
28. Hindmarsh PC, Dattani MT. Use of growth hormone in children. Nat Clin Pract Endocrinol Metab 2006; 2: 260-268.
29. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000; 342: 1633-1637.
30. Mauras N, George D, Evans J, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002; 51: 127-135.
31. Wong SC, Hassan K, McGrogan P, et al. The effects of recombinant growth hormone on linear growth in children with Crohn's disease and short stature. J Pediatr Endocrinol Metab 2007; 20: 1315-1324.
32. Baker J, Liu JP, Robertson EJ, et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82.
33. Parks JS, Brown MR, Faase ME. The spectrum of growth-hormone insensitivity. J Pediatr 1997; 131: S45-S50.
34. Daughaday WH. A personal history of the origin of the somatomedin hypothesis and recent challenges to its validity. Perspect Biol Med 1989; 32: 194-211.
35. Daughaday WH, Hall K, Raben MS, et al. Somatomedin: proposed designation for sulphation factor. Nature 1972; 235: 107.
36. Isaksson OGP, Jansson JO, Gause IAM. Growth hormone stimulates longitudinal bone growth directly. Science 1982; 216: 1237-1239.
37. Liu JL, Yakar S, LeRoith D. Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system. Proc Soc Exp Biol Med 2000; 223: 344-351.
38. Green H, Morikawa M, Nixon T. A dual effector theory of growth-hormone action. Differentiation 1985; 29: 195-198.
39. Zezulak KM, Green H. The generation of insulin-like growth factor-1-sensitive cells by growth hormone action. Science 1986; 233: 551-553.
40. Wang J, Zhou J, Bondy CA. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J 1999; 13: 1985-1990.
41. Yakar S, Liu JL, Butler A, et al. Normal growth and development in the absence of hepatic insulin-like growth factor 1. Proc Natl Acad Sci U S A 1999; 96: 7324-7329.
42. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110: 771-781.
43. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008; 29: 535-559.
44. Madsen K, Friberg U, Roos P, et al. Growth hormone stimulates the proliferation of cultured chondrocytes from rabbit ear and rat rib growth cartilage. Nature 1983; 304: 545-547.
45. Livne E, Laufer D, Blumenfeld I. Comparison of in vitro response to growth hormone by chondrocytes from mandibular condyle cartilage of young and old mice. Calcif Tissue Int 1997; 61: 62-67.
46. Hutchison MR, Bassett MH, White PC. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology 2007; 148: 3122-3130.
47. Flores-Morales A, Greenhalgh CJ, Norstedt G, et al. Negative regulation of growth hormone receptor signaling. Mol Endocrinol 2006; 20: 241-253
48. Brooks AJ, Wooh JW, Tunny KA, et al. Growth hormone receptor; mechanism of action. Int J Biochem Cell Biol 2008; 40: 1984-1989.
49. Waters MJ, Hoang HN, Fairlie DP, et al. New insights into growth hormone action. J Mol Endocrinol 2006; 36: 1-7.
50. Uyttendaele I, Lemmens I, Verhee A, et al. Mammalian protein-protein interaction trap (MAPPIT) analysis of STAT5, CIS, and SOCS2 interactions with the growth hormone receptor. Mol Endocrinol 2007; 21: 2821-2831.
51. Smit LS, Meyer DJ, Billestrup N, et al. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3 and 5 by GH. Mol Endocrinol 1996; 10: 519-533.
52. Herrington J, Smit LS, Schwartz J, et al. The role of STAT proteins in growth hormone signaling. Oncogene 2000; 19: 2585-2597.
53. Han YL, Leaman DW, Watling D, et al. Participation of JAK and STAT proteins in growth hormone-induced signaling. J Biol Chem 1996; 271: 5947-5952.
54. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19: 2628-2637.
55. Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 2000; 106: 1095-1103.
56. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997; 94: 3801-3804.
57. Durbin JE, Hackenmiller R, Simon MC, et al. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84: 443-450.
58. Meraz MA, White JM, Sheehan KCF, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996; 84: 431-442.
59. Kofoed EM, Hwa, V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003; 349: 1139-1147.
60. Woelfle J, Chia DJ, Rotwein P. Mechanisms of growth hormone (GH) action - Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem 2003; 278: 51261-51266.
61. Woelfle J, Billiard J, Rotwein P. Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem 2003; 278: 22696-22702.
62. Klammt J, Pfäffle R, Werner H, et al. IGF signaling defects as causes of growth failure and IUGR. Trends Endocrinol Metab 2008; 19: 197-205.
63. Baxter RC, Martin JL. Structure of the Mr 140, 000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci U S A 1989; 86: 6898-6902.
64. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854.
65. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801-831.
66. Jones JI, D'Ercole AJ, Camacho-Hubner C, et al. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci U S A 1991; 88: 7481-7485.
67. Hoshi K, Ogata N, Shimoaka T, et al. Deficiency of insulin receptor substrate-1 impairs skeletal growth through early closure of epiphyseal cartilage. J Bone Miner Res 2004; 19: 214-223.
68. Michaylira CZ, Ramocki NM, Simmons JG, et al. Haplotype insufficiency for suppressor of cytokine signaling-2 enhances intestinal growth and promotes polyp formation in growth hormone-transgenic mice. Endocrinology 2006; 147: 1632-1641.
69. Stahl N, Farruggella TJ, Boulton TG, et al. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995; 267: 1349-1353.
70. Zong CS, Chan J, Levy DE, et al. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 2000; 275: 15099-15105.
71. Yadav A, Kalita A, Dhillon S, et al. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J Biol Chem 2005; 280: 31830-31840.
72. Shimoaka T, Kamekura S, Chikuda H, et al. Impairment of bone healing by insulin receptor substrate-1 deficiency. J Biol Chem 2004; 279: 15314-15322.
73. Ulici V, Hoenselaar K, Gillespie JR, et al. The PI3K pathway regulates endochondral bone growth through control of hypertrophic chondrocyte differentiation. BMC Dev Biol 2008; 8: 40.
74. Macrae VE, Burdon T, Ahmed SF, et al. Ceramide inhibition of chondrocyte proliferation and bone growth is IGF-I independent. J Endocrinol 2006; 191: 369-377.
75. De Benedetti F, Meazza C, Oliveri M, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001; 142: 4818-4826.
76. Davies UM, Jones J, Reeve J, et al. Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 1997; 40: 332-340.
77. Touati G, Prieur AM, Ruiz JC, et al. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab 1998; 83: 403-409.
78. Bechtold S, Ripperger P, Muhlbayer D, et al. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 2001; 86: 5737-5744.
79. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-650.
80. Li P, Schwartz EM. The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003; 25: 19-33.
81. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995; 7: 15-25.
82. De Benedetti F, Pignatti P, Vivarelli M, et al. In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. J Immunol 2001; 166: 4334-4340.
83. Barreca A, Ketelslegers JM, Arvigo M, et al. Decreased acid-labile subunit (ALS) levels by endotoxin in vivo and by interleukin-1[beta] in vitro. Growth Horm IGF Res 1998; 8: 217-223.
84. Delhanty PJD. Interleukin-1[beta] suppresses growth hormone-induced acid-labile subunit mRNA levels and secretion in primary hepatocytes. Biochem Biophys Res Commun 1998; 243: 269-272.
85. Lang CH, Fan J, Cooney R, et al. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol Endocrinol Metab 1996; 270: E430-E437.
86. Lang CH, Nystrom GJ, Frost RA. Regulation of IGF binding protein-1 in Hep G2 cells by cytokines and reactive oxygen species. Am J Physiol Gastrointest Liver Physiol 1999; 276: G719-G727.
87. Frost RA, Nystrom GJ, Lang CH. Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1{beta}: requirement of the mitogen-activated protein kinase pathway. Endocrinology 2000; 141: 3156-3164.
88. de Hooge, ASK, van de Loo FAG, Bennink MB, et al. Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: a comparative study in gene-deficient mice. Arthritis Rheum 2003; 48: 1750-1761.
89. Macrae VE, Farquharson C, Ahmed SF. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol 2006; 189: 319-328.
90. Martensson K, Chrysis D, Savendahl L. Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004; 19: 1805-1812.
91. Aizawa T, Kon T, Einhorn TA, et al. Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res 2001; 19: 785-796.
92. Horiguchi M, Akiyama H, Ito H, et al. Tumour necrosis factor-alpha up-regulates the expression of BMP-4 mRNA but inhibits chondrogenesis in mouse clonal chondrogenic EC cells, ATDC5. Cytokine 2000; 12: 526-530.
93. Goldring MB, Birkhead J, Sandell LJ, et al. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988; 82: 2026-2037.
94. Legendre F, Dudhia J, Pujol JP, et al. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. J Biol Chem 2003; 278: 2903-2912.
95. Reynolds JJ, Hembry RM, Meikle MC. Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv Det Res 1994; 8: 312-319.
96. Broussard SR, McCusker RH, Novakofski JE, et al. IL-1{beta} impairs insulin-like growth factor I-induced differentiation and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. J Immunol 2004; 172: 7713-7720.
97. Kenchappa P, Yadav A, Singh G, et al. Rescue of TNF-alpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J Neurosci Res 2004; 76: 466-474.
98. Matsumoto T, Tsukazaki T, Enomoto H, et al. Effects of interleukin-1 beta on insulin-like growth factor-I autocrine/paracrine axis in cultured rat articular chondrocytes. Ann Rheum Dis 1994; 53: 128-133.
99. Shen WH, Zhou JH, Broussard SR, et al. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res 2002; 62: 4746-4756.
100. Strle K, Broussard SR, McCusker RH, et al. Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology 2004; 145: 4592-4602.
101. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway. J Immunol 2001; 166: 3491-3498.
102. Boisclair YR, Wang J, Shi J, et al. Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1beta on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells. J Biol Chem 2000; 275: 3841-3847.
103. Liu XB, Shi Q, Sigmund CD. Interleukin-1 beta attenuates renin gene expression via a mitogen-activated protein kinase kinase-extracellular signal-regulated kinase and signal transducer and activator of transcription 3-dependent mechanism in As4. 1 cells. Endocrinology 2006; 147: 6011-6018.
104. Shi H, Tzameli I, Bjorbaek C, et al. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 2004; 279: 34733-34740.
105. Denson LA, Held MA, Menon RK, et al. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol 2003; 284: G646-G654.
106. Tollet-Egnell P, Flores-Morales A, Stavreus-Evers A, et al. Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Endocrinology 1999; 140: 3693-3704.
107. Turnley AM. Role of SOCS2 in growth hormone actions. Trends Endocrinol Metab 2005; 16: 53-58.
108. Starr R, Metcalf D, Elefanty AG, et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A 1998; 95: 14395-14399.
109. Alexander WS, Starr R, Fenner JE, et al. SOCS1 is a critical inhibitor of interferon [gamma] signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999; 98: 597-608.
110. Roberts AW, Robb L, Rakar S, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 2001; 98: 9324-9329.
111. Adams TE, Hansen JA, Starr R, et al. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem 1998; 273: 1285-1287.
112. Hansen JA, Lindberg K, Hilton DJ, et al. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol 1999; 13: 1832-1843.
113. Inaba M, Saito H, Fujimoto M, et al. Suppressor of cytokine signaling 1 suppresses muscle differentiation through modulation of IGF-I receptor signal transduction. Biochem Biophys Res Commun 2005; 328: 953-961.
114. Rico-Bautista E, Greenhalgh CJ, Tollet-Egnell P, et al. Suppressor of cytokine signaling-2 deficiency induces molecular and metabolic changes that partially overlap with growth hormone-dependent effects. Mol Endocrinol 2005; 19: 781-793.
115. Macrae VE, Horvat S, Pells SC, et al. Increased bone mass, altered trabecular architecture and modified growth plate organization in the growing skeleton of SOCS2 deficient mice. J Cell Physiol 2009; 218: 276-284.
116. Lorentzon M, Greenhalgh CJ, Mohan S, et al. Reduced bone mineral density in SOCS-2-deficient mice. Pediatr Res 2005; 57: 223-226.
117. Greenhalgh CJ, Alexander WS. Suppressors of cytokine signalling and regulation of growth hormone action. Growth Horm IGF Res 2004; 14: 200-206.
118. LeRoith D, Nissley P. Knock your SOCS off! J Clin Invest 2005; 115: 233-236.
119. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 2005; 115: 397-406.
120. Greenhalgh CJ, Bertolino P, Asa SL, et al. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 2002; 16: 1394-1406.
121. Vidal OM, Merino R, Rico-Bautista E, et al. In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol Endocrinol 2007; 21: 293-311.
122. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-465.
123. Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999; 274: 35553-35561.
124. Dey BR, Spence SL, Nissley P, et al. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem 1998; 273: 24095-24101.
125. Michaylira CZ, Simmons JG, Ramocki NM, et al. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo. Am J Physiol Gastrointest Liver Physiol 2006; 291: G472-G481.
126. Horvat S, Medrano JF. Lack of Socs2 expression causes the high-growth phenotype in mice. Genomics 2001; 72: 209-212.
127. Horvat S, Medrano JF. Interval mapping of high growth (hg), a major locus that increases weight gain in mice. Genetics 1995; 139: 1737-1748.
128. Horvat S, Medrano JF. A 500-kb YAC and BAC contig encompassing the high-growth deletion in mouse chromosome 10 and identification of the murine Raidd/Cradd gene in the candidate region. Genomics 1998; 54: 159-164.
129. Greenhalgh CJ, Metcalf D, Thaus AL, et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002; 277: 40181-40184.
130. Favre H, Benhamou A, Finidori J, et al. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 1999; 453: 63-66.
131. Leung KC, Doyle N, Ballesteros M, et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci U S A 2003; 100: 1016-1021.
132. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-387.
133. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-921.
134. Dogusan Z, Hooghe-Peters EL, Berus D, et al. Expression of SOCS genes in normal and leukemic human leukocytes stimulated by prolactin, growth hormone and cytokines. J Neuroimmunol 2000; 109: 34-39.
135. Macrae VE, Farquharson C, Ahmed SF. The pathophysiology of the growth plate in juvenile idiopathic arthritis. Rheumatology 2006; 45: 11-19.